newsfilter
← Latest News
GlobeNewswire·

Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results

FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia Evaluation of strategic alternatives BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) --